DDRC  2012 articles (Please click)

According to the report released in September 2011 announcing scientists' rankings based on Essential Science Indicators, Dr. Reza Malekzadeh, the premier professor in Tehran University of Medical Sciences, stands in the list of top 1% of scientists across the world in the field of clinical medicine.
Based on this report on scientists' rankings according to Essential Science Indicators, along with three other top scientists in the country, Dr. Mohammad Abdollahi, Dr. Mohammad Reza Zarrindast, and Dr. Ahmad Reza Dehpour, Dr. Reza Malekzadeh is among the top 1% of scientists across the world in the field of clinical medicine.
According to the report released by the Deputy of Research and the last report on scientists' rankings based on Essential Science Indicators, the name of Dr. Reza Malekzadeh appears among the top 1% of the world scientists along with three other Iranian scientists, Dr. Mohammad Abdollahi, Dr. Mohammad Reza Zarrindast, and Dr. Ahmad Reza Dehpour.
Accordingly, the list of premier scientists in the filed of biomedical science in the country, is extended from 3 to 4 scientists. This is the first time in Iran that one of the premier researchers in the field of clinical medicine appears in the list of top 1% of scientists who have achieved the highest citation impact scores in the world.
Based on ESI report in September 2011, Dr. Mohammad Abdollahi with 2449 citations has achieved the 455th rank in the world and the first rank in the country in the field of Pharmacology & Toxicology. Next to him, Dr. Mohammad Reza Zarrindast with 1614 citations has achieved the 1798th rank in Pharmacology & Toxicology and the 3542th in Behavioral and Neuroscience in the world and stands in the second position in the country.
It is worth mentioning that Dr. Reza Malekzadeh has achieved the only national rank in the field of clinical medicine and the 3rd overall rank in the country with 1591 citations. The 4th rank in the country belongs to Dr. Ahmad Reza Dehpour who has achieved the 1755th rank in the world in the field of Pharmacology & Toxicology with 1401 citations.
This ranking system is based on analysis of data on top 1% of scientist who had the most citations in specified fields in ISI Web of Sciences from January 2001 to the end of June 2010. The data is updated every 2 months.

Dr. Asghar Rastgar, Professor of Internal Medicine and Nephrology from Yale University in the United States, visited DDRC. In a meeting which was held on July 11th at 9:00 AM in the conference hall of DDRC, Dr. Rastgar discussed a project on Chronic Kidney Diseases (CKD) embedded in Golestan Cohort Study, which will be supervised by Dr. Iraj Najafi, Assistant Professor of nephrology, Dr. Reza Malekzadeh, Professor of gastroenterology and hepatology, and other members of DDRC. In this meeting, the design of the new project was discussed as well.

 

On July 7th 2011 at 11:00 am, Dr. Sanford Martin Dawsey had a Lecture about “PAH as a universal carcinogen for upper GI tract cancer " Dr Malekzadeh (Head of DDRI), faculty members and gastric fellows attend  in this Conference.
Dr Dawsey summarized the evidence regarding the role of polycyclic aromatic hydrocarbons (PAH’s) in esophageal cancer. PAHs are a class of carcinogens which are produced mainly by incomplete fuel combustion. Environmental sources of PAH exposure include cigarette smoke, air pollution, coal and diet. Cross-sectional studies in high-incidence areas of esophageal squamous cell carcinoma (ESCC) in Linxian (China) and Golestan Province (Iran) indicate that the inhabitants of these areas are highly exposed to PAHs. While tobacco smoking is a known risk factor for ESCC and a major source of exposure to PAHs, high exposure levels to PAHs in Golestan were observed among non-smokers as well as smokers, and only 15% of the variance in PAH levels in urine was explained by known factors, such as age, sex, place of residence (rural vs. urban), and tobacco use. A recent case-control study in Golestan Province reported higher levels of antibodies against benzo[a]pyrene diol epoxide-I-modified guanosine in non-tumoral esophageal biopsies from patients with biopsy-proven ESCC than in biopsies from control subjects, which suggests a causal role for PAHs in esophageal carcinogenesis in the region

In Iran, preventing chronic diseases in high risk people is among main health priorities. Strategies for primary and secondary prevention include controlling risk factors (e.g. hypertension and dyslipidemia) and prescribing medications. Regarding medications, instead of separate pills, a combination of them has been developed named as Polypill, which is currently examined on individuals over 50 in Golestan Cohort Study.
Dr. Marshall is an epidemiologist and biostatistician in Birmangham/UK and a public health planning fellow in US. He had a 6-day trip to Iran from June 8 to June 13, 2011. Accompanying a group of the executive board and Dr. Malekzadeh, Dr. Marshall travelled to Gonbad Kavous district which is the main site of Polypill research project. The aims of this trip include: visiting the recruitment of eligible subjects into the project (which will be completed within one year and half); visiting the follow-up phase of these subjects for 5 years in Gonbad Kavous; holding sessions in Aq Ghola district to recruit colleagues with the attendance of physicians and Behvarzes in health houses and health centers and responding their questions; and visiting the Cardiovascular Research Center in Isfahan which is one of the collaborating centers in this project.
It is worth mentioning that based on preceding decisions and planning, Digestive Disease Research Center aims to conduct this project in two other districts: Aq Ghola and Kolaleh.

 

The Digestive Disease Week (DDW)
was held from May 8th to May 10th in Chicago, USA.
on May 9th, Professor Reza Malekzadeh,the head of the Digestive Disease Research Institute from Iran,presentes a lecture in DDW with the following title,
The Impact of Intravenous Drug Use on Spontaneous
Hepatitis C Clearance: Experience from a Large Cohort Population Study

Abstract:

Background and Aims: Acute hepatitis C infection usually ends in chronic infection, while in a minority of patients it is spontaneously cleared. The current population-based study is performed on a large cohort in Golestanprovince of Iran to examine the demographic correlates of Chronic HCV (CHCV).

Methods: Serum samples used in this study had been stored in biorepository of Golestan Cohort Study. Serum samples were evaluated for anti-hepatitis C Virus by third generation Enzyme-linked immunosorbent assay (ELISA). Subjects who tested positive were then invited and tested by Recombinant ImmunoblotAssay (RIBA)and Ribonucleic Acid Polymerase Chain Reaction test (PCR). If testedpositive forRIBA, subjects were recalled and the two tests were re-done after 6 months. Those subjects who again tested positive for RIBA but negative for PCR were marked as cases of SC

Results:49338 serum samples were evaluated. The prevalence of chronic hepatitis C infection based on PCR results was 0.31%. Among those who had acquired hepatitis C, the rate of SC was 38%.In multivariate analysis, both Intra-Venous Drug Use (OR=3.271, 95% CI: 1.784-6.000, p-value<0.001) and Non-Intra-Venous Drug Use (OR=1.901, 95% CI: 1.068-3.386, p-value=0.029) were significant correlates of CHCV versus SC

Conclusions: In our study, Drug Use whether intravenous or non-intravenous have been the significant correlates of CHCV, for which several underlying mechanisms can be postulated. including repeated contacts with antigen .

Key words: hepatitis C; spontaneous clearance; intra-venous drug use
 

Management conference

1390/2/6.. 2011/4/26

A 16 y old women come with 1 month hx of RUQ pain with radiation to back sometime's aggravating with food ,worse in night and morning

please dowmload attached pdf_file